Verified Nov 2026
Other
·

Nanjing, Jiangsu
·
Since 2023
Simcere Zaiming is an oncology-focused biopharmaceutical company headquartered in Nanjing, Jiangsu, China, founded in 2023 as a subsidiary of Simcere Pharmaceutical Group Limited. With 50–100 employees, it conducts research, development, manufacturing, and commercialization of cancer therapeutics. The company has advanced multiple programs through partnerships, including an antibody drug conjugate expanded into United States trials in 2025.
Simcere Zaiming at a glance
Employees
50-100
Founded
2023
Headquarters
Nanjing, Jiangsu
Industries
Automotive
Electric Vehicles
Medical
Overview
Simcere Zaiming is an oncology-focused biopharmaceutical company headquartered in Nanjing, Jiangsu, China, founded in 2023 as a subsidiary of Simcere Pharmaceutical Group Limited. With 50–100 employees, it conducts research, development, manufacturing, and commercialization of cancer therapeutics. The company has advanced multiple programs through partnerships, including an antibody drug conjugate expanded into United States trials in 2025.
At a glance
Attribute | Detail |
|---|---|
Founded | 2023 |
Headquarters | Nanjing, Jiangsu |
Employees | 50-100 |
What Simcere Zaiming makes
The company develops oncology drugs including COSELA®, Endostar®, and Envafolimab®, alongside early-stage programs such as antibody drug conjugates and dual-target antibody treatments for inflammatory bowel disease.
Latest developments
2026-11-09 — Simcere’s SIM0709 Wins German Phase 1 Clearance Under EUR1bn BI Deal – Minichart (minichart.com.sg)
2026-05-06 — Simcere Pharmaceutical Group Limited (simcere.com)
2026-01-27 — Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease (streetinsider.com)
2025-12-22 — Ipsen expands early development pipeline with Simcere Zaiming’s innovative antibody drug conjugate (ipsen.com)
2025-10-16 — NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States - NextCure, Inc. (nextcure.com)
2025-06-16 — NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6 - NextCure, Inc. (nextcure.com)
Company details
Simcere Zaiming operates a complete value chain encompassing internal R&D, manufacturing, and commercialization, and pursues strategic global partnerships to expand its therapeutic portfolio and market reach. Simcere Zaiming was founded in 2023, has an estimated 50-100 employees, and is headquartered in Nanjing, Jiangsu.
Frequently asked questions
What does Simcere Zaiming do?
Simcere Zaiming is an oncology-focused biopharmaceutical company headquartered in Nanjing, Jiangsu, China, founded in 2023 as a subsidiary of Simcere Pharmaceutical Group Limited. With 50–100 employees, it conducts research, development, manufacturing, and commercialization of cancer therapeutics. The company has advanced multiple programs through partnerships, including an antibody drug conjugate expanded into United States trials in 2025.
Where is Simcere Zaiming headquartered?
Simcere Zaiming is headquartered in Nanjing, Jiangsu.
When was Simcere Zaiming founded?
Simcere Zaiming was founded in 2023.
How big is Simcere Zaiming?
Simcere Zaiming has an estimated 50-100 employees.
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.
